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1. INTRODUCTION 
 Pharmaceutical Analysis deals not only with medicaments (drugs and 
formulations), but also with their precursors i.e. with the raw material whose degree 
of purity, which in turn decides the quality of medicaments. The quality of a drug is 
determined, after establishing its authenticity, which is carried by testing its purity 
and the quality of the pure substance in the drug and its formulations.[1-7] 
 Analytical chemistry has got a pivot role to play in determination of quality 
of medicines as quality is important and essential aspect to be considered in every 
product or service. Quality is more vital in medicines as it is related to life. A 
compromise in pharmaceutical quality is nothing but playing with the life of 
consumer. Application of analytical chemistry in pharmacy is termed as 
pharmaceutical analysis. The terms quality, quality control, quality assuarance, total 
quality management are correlated. The ultimate goal of all these is to provide a 
product with good quality, safety, efficiency, purity, strength and identity. 
 General terms associated with chemical analysis 
 Analytical technique 
It  is  the  fundamental  scientific  phenomenon  that  is  proved  useful  for 
providing information on the composition of substances. 
 Analytical method 
The method is the specific application of technique to solve the analytical 
problem. 
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  Protocol 
The most specific description of a method is known as protocol. 
  Procedure 
 A procedure is written instructions for carrying out a method.  
The “standard methods” developed by the ASTM (American Society for 
Testing Materials) and the AOAC (Association  of  Official  Analytical  Chemists). 
It only provides the general steps to be followed.  
 Pharmaceutical analysis is broadly classified into two branches, namely 
qualitative analysis and quantitative analysis. 
 A.  Qualitative analysis: It deals with the identification and establishment 
of the identity of analyte among elements or compounds present in the sample. 
 B.  Quantitative analysis: It deals with the quanification of the analyte 
present in the matter of sample. 
 The determination of the quality and of quantity of the sample is done the 
application of analytical methods. 
Analytical methods are classified into two types 
  Instrumental methods. 
  Non-instrumental methods. 
CHROMATOGRAPHY 
The term Chromatography (in Greek, khromatos means 
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means written) means colourwriting. The term chromatography and its principles 
were discovered  in  1903  by Mikhiltswett.  Chromatography is the separation  of 
mixture of components into individual components by using a stationary phase and a 
mobile phase.  
Chromatography is method of separating mixtures and identifying their 
components i.e. it’s a separation method that exploits the differences in partitioning 
behaviour of analyse between a mobile phase and a stationary phase to separate 
components in a mixture. Components of a mixture may be interacting with the 
stationary phase based on charge (ion-ion-interactions, ion-dipole-interactions), 
Vander Waal’s forces, relative solubility or adsorption (hydrophobic interactions, 
specific affinity). 
Chromatography may be preparative or analytical. Preparative chromatography 
seeks to separate the components of a mixture for further use (and is thus a form 
of purification). Analytical chromatography normally operates with smaller  
amounts  of  material  and  seeks  to  measure  the  relative  proportions  of analytes 
in a mixture. The two are not mutually exclusive. 
Classification of chromatographic methods 
    Gas – solid chromatography. 
    Gas – liquid chromatography. 
    Solid – liquid chromatography. 
    Liquid- liquid chromatography.  
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HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC): 
            High-performance liquid chromatography is a chromatographic technique 
used to separate the components in a mixture, to identify each component, and to 
quantify each component .The method involves a liquid sample being passed over a 
solid adsorbent material packed into a column using a flow of liquid solvent. Each 
analyte in the sample interacts slightly differently with the adsorbent material, thus 
retarding the flow of the analytes. If the interaction is weak, and the analytes flow 
off the column in a short amount of time, and if the interaction is strong, then the 
elution time is long. 
           Chromatography may be defined as a method of separating a mixture of 
components into individual components through equilibrium distribution between 
two phases.  
        The HPLC method was considered the choice of estimation, since this method 
is the most powerful of all chromatographic and other separative methods. The 
HPLC method has enabled analytical chemist to attain great success in solving his 
analytical problems. The HPLC is the method of choice in the field of analytical 
chemistry, since this method is specific, robust, linear, precise, and accurate and the 
limit of detection is low and also it offers the following advantages. 
The schematic representation of an HPLC instrument typically includes a 
sampler, pumps, and a detector. The sampler brings the sample mixture into the 
mobile phase stream which carries it into the column. The pumps deliver the desired 
flow and composition of the mobile phase through the column. The detector 
generates a signal proportional to the amount of sample component emerging from 
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the column, hence  allowing for quantitative analysis of the sample components .A 
digital microprocessor and user software  control the HPLC instrument and provide 
data analysis. Some models of mechanical pumps in a HPLC instrument can mix 
multiple solvents together in ratios changing in time, generating a composition 
gradient in the mobile phase. Various detectors are in common use, such as UV/Vis, 
photodiode array (PDA) or Refractive index (RI). 
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) 
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SCHEMATIC REPRESENTATION OF HPLC SYSTEM 
INTRODUCTION TO HPLC METHOD DEVELOPMENT 
Method development has following steps: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 High-performance liquid chromatography (HPLC) is the fastest growing 
analytical technique for analysis of drugs. Its simplicity, high specificity and wide 
range of sensitivity make it ideal for the analysis of many drugs in both dosage 
forms and biological fluids. 
Collect information on sample, define separation goals 
Need for special HPLC procedure, sample pretreatment, etc. 
Choose detector and detector settings 
Choose LC method, preliminary run, select best separation conditions 
Optimize separation conditions 
Check for problems 
Optimize separation conditions 
Recover purified material Qualitative method 
Validate method for release to routine laboratory 
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The HPLC offers the following advantages. 
  Speed (many analysis can be accomplished in 20 min or less). 
  Greater sensitivity (various detectors can be employed). 
  Improved resolution (wide variety of stationary phases). 
  Reusable columns (expensive columns but can be used for many analysis). 
  Ideal for the substances of low viscosity. 
  Easy sample recovery, handling and maintenance. 
  Instrumentation leads itself to automation and quantification (less time and 
less labour). 
  Precise and reproducible 
  Integrator itself does calculations.  
PERFORMANCE CALCULATIONS SYSTEM SUITABILITY 
PARAMETERS 
1)  Retention time (tR) 
2)  Resolution (RS) 
3)  Capacity factor (k`) 
4)  Selectivity (α) 
5)  Number of Theoretical plates (N) 
6)  HETP 
7)  Asymmetry factor 
8)  Tailing factor 
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1) Retention time 
Chromatographic retention is to measure the time between the injection point 
and maximum of the detector response for correspondent compound. This parameter 
called “retention time” is inversely proportional to the eluent flow rate. 
2) Resolution 
The goal of most HPLC analyses is the separation of one or more analytes in 
the sample from all other components present. Resolution (Rs) is a measure of the 
degree of separation of two adjacent analytes. Resolution of two adjacent band is 
defined as the distance between band peaks divided by the average band width. 
Retention and band width are measured in units of time. 
 
Where, 
Rt1 and Rt2 are the retention times of components 1 and 2 
W1 and W2 are peak widths of components 1 and 2. 
RS ≥ 2.0 is a desirable target for method development. 
3) Capacity factor (K’) 
It is a measure of a sample peak in the chromatogram being specific for a 
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given compound, a parameter which specifies of a substance to be separated. 
 
The retention factor k is given by the equation 
k= (tR – t0  ) / t0 
Where, 
‘tR’ is the band retention time 
‘t0’ is the column dead time. 
4) Selectivity (α) 
The selectivity α is a measure of relative retention of two components in a 
mixture.  The  ideal  value  of  selectivity  is  2.  It  can  be  calculated  by  using  the 
following formula. 
  
V2   V0  
 
            V1   V0 
Where, V0 is the void volume of the column and V2 and V1 are the 
retention volumes of the second and the first peak, respectively. 
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COLUMN EFFICIENCY & PLATE NUMBER 
The number of theoretical plates or plate number is a measure of column 
efficiency. An efficient column produces sharp peaks and can separate many sample 
components in a relatively short time. Theoretical plates (N) are defined as the 
square of the ratio of the retention time divided by the standard deviation of the peak 
(σ). 
 
Another way to express efficiency of column is by calculating height 
equivalents of theoretical plates (HETP). 
H = L/N 
 Where H = HETP; L = Length of the column; N = number of theoretical 
plates. Lower the HETP, higher is the efficiency of the column, i.e., higher the 
theoretical plates more efficient the column. 
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7) Peak asymmetry 
Peak asymmetry factor as can be used as a criterion of column performance. 
The peak half width, divided by the corresponding front half width, a gives the 
asymmetry factor. A    b 
s  
a 
Where, 
 ‘b’, is the distance at 50% peak height between leading edge to the 
perpendicular drawn from the peak maxima 
 ‘a’, is the width of the peak at half the peak height. 
8) Tailing factor 
The tailing factor T, a measure of peak symmetry, is unity for perfectly 
symmetrical peaks and its value increases as tailing becomes more pronounced. 
In some cases, values less than unity may be observed. As peak asymmetry 
increases, integration, hence precision becomes less reliable. 
According to USP (2000) Peak-tailing factor can be calculated by using the 
formula 
T = W0.05/2 f 
Where, 
‘W0.05’ is the width of the peak at 5% height and 
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‘f’ is the distance from the peak maximum to the leading edge of the peak, 
the distance being measured at a point 50% of the peak height from the base line. 
MOBILE PHASE: 
 Mobile phases used for HPLC typically are mixtures of organic solvents and 
water or aqueous buffers. The following points should also be considered when 
choosing a mobile phase. 
1. It is essential to establish that the drug is stable in the mobile phase for at 
least the duration of the analysis. 
2. Excessive salt concentrations should be avoided. High salt concentrations 
can result in precipitation, which can damage HPLC equipment. 
DETECTORS: 
Detectors used depend upon the property of the compounds to be separated. 
Optical detectors are most frequently used. 
                   UV-Ultraviolet Detector 
                   RI – Refractive Index (Universal analyte detector) 
                   FD – Fluorescence detector 
                   MS – Mass Spectroscopic detector 
                   PDA - Photo Diode Array Detector 
                  Conductivity Detector 
                  Amperometric  Detector 
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HPLC METHOD DEVELOPMENT: 
A good method development strategy should require only as many 
experimental runs as are necessary to achieve the desired final result. Finally method 
development should be as simple as possible and it should allow the use of 
sophisticated tools such as computer modelling. During initial method development, 
a set of initial conditions (detector, column, mobile phase) is selected to obtain the 
first “scouting” chromatograms of the sample. In most cases, these are based on 
reversed-phase separations on a C18 column with UV detection. 
SELECTION OF CHROMATOGRAPHIC MODE: 
Reversed-Phase chromatography (RPC), the most common mode for small-
organic molecules. Note that ionisable compounds (acids and bases) are often 
separated by RPC with buffered mobile phases (to keep the analytes in a non- 
ionized state) or with ion-pairing reagents. In reverse phase mode, the mobile phase 
is comparatively more polar than the stationary phase. For the separation of polar or 
moderately polar compounds, the most preferred mode is reverse phase. The nature 
of the analyte is the primary factor in the selection of the mode of separation .A 
second factor is the nature of the matrix 
SAMPLE PREPARATION: 
Samples occur in various forms 
 Solutions ready for injection 
 Solutions that require  dilution,  buffering,  addition  of  an  internal 
standard or other volumetric manipulation 
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 Solids must be dissolved or extracted 
 Samples that require pre-treatment to remove interferences and/or 
protect the column or equipment from damage. 
CHOICE OF THE COLUMN: 
Selection of the column is the first and the most important step in method 
development. Some of the important parameters to be considered while selecting 
chromatographic column. 
  Length and diameter of the column 
  Packing material 
  Shape of the particles 
  Size of the particles 
SELECTION OF SOLVENT DELIVERY SYSTEM: 
Chromatographic separation with isocratic elution i.e. all constituents of the 
mobile phase is mixed and pumped together as a single solvent, is always preferable 
however, gradient elution is powerful tool in achieving separation between closely 
eluting compounds or compounds having widely differing in polarities. 
SELECTION OF MOBILE PHASE: 
The primary objective in selection and optimization of mobile phase is to 
achieve optimum separation of all impurities and degradants from each other and 
from analyte peak. 
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In liquid chromatography,  the solute retention is governed by the solute 
distribution factor, which reflects the different interactions of the solute-stationary 
phase,  solute-mobile  phase,  and  mobile  phase-stationary  phase.  For  a  given 
stationary phase, the nature and the composition of which has to be judiciously 
selected in order to get appropriate and required solute retention.  
    Buffer and its strength 
    pH of the buffer or pH of the mobile phase 
    Mobile phase composition 
SELECTION OF FLOW RATE 
Generally flow rate shall not be more than 2.0 ml/min. The flow rate shall be 
selected based on the following data. 
    Retention time 
    Column back pressure 
    Resolution between the peaks 
    Peak symmetries 
The flow rate which gives least retention times, good peak symmetries, least back 
pressures and better separation will be selected. 
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PERFORMANCE CALCULATIONS SYSTEM SUITABILITY PARAMETERS 
1)  Retention time (tR) 
2)  Resolution (RS) 
3)  Capacity factor (k`) 
4)  Selectivity (α) 
5)  Number of Theoretical plates (N) 
6)  HETP 
7)  Asymmetry factor 
8)  Tailing factor 
ANALYTICAL METHOD VALIDATION 
Method validation can be defined as per ICH as, “Establishing documented 
evidence, which provides a high degree of assurance that a specific activity will 
consistently produce a desired result or product meeting its predetermined 
specifications and quality characteristics”. 
SPECIFICITY/SELECTIVITY 
The terms selectivity and specificity are often used interchangeably. 
According to ICH, the term specific generally refers to a method that produces 
distinguishable responses for a single analyse of number of chemical entities that 
may or may not be distinguished from each other. If the response is distinguished 
from all other responses, the method is said to be selective. 
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LINEARITY: 
Linearity of an analytical procedure is its ability (with in a given range) to 
obtain test results which are directly proportional the concentration (amount) of 
analyte in the sample. It may be demonstrated directly on the drug substance (by 
dilution of a standard stock solution) and/or separate weighing of synthetic mixtures 
of the drug product components, using the proposed procedure. Linearity should be 
evaluated by visual inspection of a plot of signals as a function of analyte 
concentration or content. If there is a linear relationship, test results should be 
evaluated  by  appropriate  statistical  methods,  for  example,  by  calculation  of  a 
regression line by the method of least squares. 
RANGE: 
Range is the interval between the upper and lower concentration  of the analyte 
in the sample for which it has a suitable level of precision, accuracy and linearity. 
ACCURACY: 
Accuracy is the measure of the closeness of the experimental value to that of 
the true value. Accuracy should be established across the specified range of the 
analytical procedure. 
PRECISION: 
Precision is the measure of how close the data values are to each other for a 
series of measurements under the same analytical conditions obtained from multiple 
sampling of the same homogeneous sample. Precision may be considered at three 
levels. 
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LIMIT OF DETECTION: 
Limit of detection is the lowest concentration of analyte in a sample which can 
be detected, but not necessarily quantitated, as an exact value under the stated 
experimental conditions. 
LIMIT OF QUANTIFICATION: 
Limit of quantification is the lowest concentration of analyte in a sample 
which can be quantitatively determined with acceptable  precision  and  accuracy 
under the stated experimental conditions. Several approaches for determining the 
quantification limit are possible, depending on whether the procedure is a non- 
instrumental or instrumental.  Approaches  other  than  those listed  below may be 
acceptable. 
RUGGEDNESS: 
Ruggedness is the degree of reproducibility of results obtained under a 
variety of conditions, such as different laboratories, analysts, instruments,  
environmental conditions, operators and materials. Ruggedness is determined by 
the analysis of aliquots from homogeneous lots in different laboratories. 
ROBUSTNESS: 
Robustness as a measure of the method's capability to remain unaffected by small, 
but deliberate variations in method parameters and provides an indication of its reliability 
during normal usage. Robustness can be partly assured with good system suitability 
specifications. The evaluation of robustness should be considered during the development 
phase and depends on the type of procedure under study. 
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Examples of typical variations are 
 Stability of analytical solutions 
 Extraction time 
  Influence of variations of pH in a mobile phase 
  Influence of variations in mobile phase composition 
  Different columns (different lots and/or suppliers) 
  Temperature 
  Flow rate. 
  Different columns (different lots and/or suppliers) 
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2. LITERATURE REVIEW [8-21] 
Ashvin dudhrejiya et al 2014 had developed a simple, precise, sensitive and 
reproducible, rapid stability indicating RP-HPLC method for the simultaneous 
estimation of Sildenafil citrate and Fluoxetine by forced degradation studies has 
been developed.  The proposed HPLC method utilizes the Shimadzu HPLC system 
on a Hiber R C-18 columns  using mobile phase consisting of Acetonitrile : 
Potassium Dihydrogen Phosphate buffer with 25 mM Triethylamine pH adjusted to 
4 with o-phosphoric acid (50:50 v/v) in an gradoamt e;itopm ,pde at a f;pw rate pf 1 
ml/min, at 23°C with a load of 20L. The detection was carried out at 223 nm. The 
retention time of Sildenafil citrate and Fluoxetine was found to be around 3.68 min 
and 5.31 min, respectively.[8] 
Prasanna Reddy et al 2010 have been developed a simple, selective, 
accurate reverse phase-high Performance Liquid Chromatographic (RP-HPLC) 
method he was developed and validated for the analysis of Sildenafil Citrate in 
pharmaceutical formulations (tablet dosage). The mobile phase was used for 
acetonitrile/phosphate buffer (70:30, v/v, pH 7.0) at a flow rate of 0.8 ml/m with UV 
detection at 228 nm. The retention time was 4.087. The proposed method is 
applicable to stability studies and routine analysis of sildenafil citrate in 
pharmaceutical formulations.[10] 
Kalyani.K et al 2015 has propossed a novel reverse phase high performance 
liquid chromatographic(RP-HPLC) method she has been developed and validated 
for simultaneous estimation of Sildenafil Citrate Dapoxetine Hydrochloride in pure 
and marketed formulations. mobile phase cosmposition of 0.1% orthophosphoric 
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acid: Acetonitrile in the ratio of 50:50 and PH adjusted to 5.0±0.1 with sodium 
hydroxide of the flow rate was 1.0 ml/min and the effluent was monitored at 287nm. 
The retenion time of Sildenafil Citrate was found to be 3.14 min and for Dapoxetine 
Hydrochrloride 4 min. The method was linear from the concentration of 12.5 -62.5 
µg/ml and 7.5-37.5 µg/ml for the estimation of Sildenafil Citrate and Dapoxetine 
Hydrochloride. The method was validated according to the guidelines of 
international conference on harmonization (ICH) and was successfully applied in the 
estimation and commercial formulations.[12] 
Nief R. Ahmed et al 2012  had done a simple, precise, rapid and accurate 
reversed–phase high performance liquid chromatographic method he has been 
developed for the determination of sildenafil citrate in a pure form, pharmaceutical 
formulations and industrial effluent samples with dilute. The method was validated 
for its linearity, precision and accuracy. The proposed method was successfully 
applied to the determination of sildenafil citrate in tablets and industrial effluent 
samples phosphoric acid as a mobile phase.[13] 
Sushma Chilukuri et al 2016 have been developed a simple, fast, accurate, 
precise, rugged, sensitive and linear Reverse Phase High Performance Liquid 
Chromatographic (RP-HPLC) method for simultaneous quantitative estimation of 
Dapoxetine hydrochloride and Sildenafil citrate in capsules and validate as per ICH 
guidelines. The optimized method uses a reverse phase column, Phenomenex Luna 
C18 (250 X 4.6 mm;5µ), a mobile phase of triethylammonium phosphate buffer (pH 
3.0):acetonitrile in the proportion of 50:50 v/v, flow rate of 1ml/min and a detection 
wavelength of 232nm using a UV detector. A simple, fast, accurate, precise, linear 
and rugged RP-HPLC method was developed for simultaneous quantitative 
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estimation of Dapoxetine hydrochloride and Sildenafil citrate in capsules and 
validated as per ICH guidelines. Hence this method can be used for the routine 
analysis of Dapoxetine hydrochloride and Sildenafil citrate in capsules in various 
pharmaceutical industries.[55] 
Prasanna reddy.B et al 2008 had done a simple, selective, accurate reverse 
phase-high performance liquid chromatographic (RP-HPLC) method he was 
developed and validated for the analysis of sildenafil citrate in pharmaceutical 
formulations. Chromatographic separation achieved isocratically on a C18 column 
(Use Inertsil C18, 5µ, 150 mm x 4.6 mm) utilizing a mobile phase of 
acetonitrile/phosphate buffer (70:30, v/v, pH 7.0) at a flow rate of 0.8 mL/m with 
UV detection at 228 nm. The retention time was 4.087. The method is accurate 
precise and linear within range 0.1-30 µg/mL (R2=0.999) concentration and was 
successfully used in monitoring left over drug. The detection limit of sildenafil 
citrate at a signal-to-noise ratio of 3 was 1.80 ng/mL in human plasma while 
quantification limit in human serum was 5.60 ng/mL. The proposed method is 
applicable to stability studies and routine analysis of sildenafil citrate in 
pharmaceutical formulations as well as in human plasma samples[11] 
Vinod Pawar et al 2012 a Simple, sensitive, specific, spectrophotometric 
method has been developed for the detection of Sildenafil citrate in pure form and 
Pharmaceutical formulations. The optimum condition for the analysis of the drug 
was established. 
Sildenafil citrate exhibiting absorption at 228nm and obeyed beers law in the 
concentration range 10 to 50µg/ml. The correlation coefficient was found to be 
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0.9998 and slope of line was found to be 0.07877. The percent S.D. for intra assay 
precision of the method was found to be 1.9976% whereas Inter assay precision was 
found to be 0.8332%. The sample solution was stable up to 24 hours. The assay 
results were found to be in good agreement with label claim. The degradation study 
was checked at different conditions like with acid, alkali, dry heat, oxidative and 
photolytic. All the results found in degradation study were satisfactory. So this 
proposed method was simple sensitive, precise, quick and useful for routine quality 
control.[15] 
  Shokry.E et al 2010 two simple, accurate, sensitive and reproducible 
methods have been developed and subsequent validated for the determination of 
Sildenafil citrate (SC) in presence of its impurities “1-methyl-4-nitro-3-n-propyl-
5pyrozole Carboxamide (MNC), 4-amino-1-methyl-3-n-propyl-5-pyrazole 
Carboxamide (AMP), 4-(2-ethoxy benzoyl amino)-1-methyl-3-n-propyl-5-pyrazole 
Carboxamide (EMC) and 5-(2-ethoxyphenyl)-1-methyl-3-n-propyl pyrazole [4,3-D] 
pyramidine-7-1(EMP)” as stability-indicating studies. In the spectrophotometric 
method, zero crossing technique was adopted for determination of the investigated 
drug in presence of impurities, by the use of derivative and derivative ratio 
techniques, respectively. While, the second method was isocratic reversedphase 
(RP) stability-indicating high-performance liquid chromatographic method, which 
was adopted for determination of Sildenafil citrate in presence of its impurities. The 
chromatographic separation was achieved isocratically by using a mobile phase of 
water and acetonitrile in a ratio of 40:60 V/V containing 50 mm triethylamine. The 
analysis was carried out using waters c18 (4.6 x 250 mm, 10 µm) at flow rate of 1.0 
ml.min-1 and the UV detection at 245 nm. All the proposed methods were validated 
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according to the International Conference on Harmonization (ICH) guidelines 
reference and successfully applied for determination of Sildenafil citrate in pure 
form, in laboratory prepared mixtures and in pharmaceutical preparations. The 
obtained results were statistically compared to the reported method of analysis for 
Sildenafil citrate and no significant differences were found.[16] 
             Thangabalan B et al  2011  had done a simple, safe and sensitive method 
of spectroscopic determination of sildenafil citrate in UV region was developed 
using 8 M urea solution as hydrotropic solubilizing agent. Sildenafil citrate showed 
λ‐max at 293 nm and beer’s law was obeyed in the concentration range of 10 – 50 
µg/ml. The results of analysis have been validated statistically and by recovery 
studies.[17] 
Kalaichelvi .R et al 2012 have been developed a simple, sensitive, accurate, 
precise and eco-friendly UV spectrosphotometric method for sildenafil citrate was 
developed. In the present investigation, a 2.0 M sodium benzoate solution was 
employed as hydrotropic solubilizing agent to solubilize poorly water-soluble drug 
sildenafil citrate for its spectrophotometric analysis. Sildenafil citrate showed λ‐max 
at 306 nm and beer’s law was obeyed in the concentration range of 10 – 50 µg/ml. 
The results of analysis have been validated statistically and by recovery studies.[18] 
Avani P et al 2015 was worked a simple, accurate, precise, reproducible and 
cost effective first derivative UV Spectrophotometric method developed and 
validated for the simultaneous estimation of Sildenafil Citrate and Aspirin in bulk as 
well as tablet dosage form. The solution of both the drugs and tablet were prepared 
in Methanol. First derivative quantitative determination of these drugs was 
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performed at 255 nm for Sildenafil Citrate at zero crossing point (ZCP) of Aspirin 
and at 291nm for Aspirin at zero crossing point (ZCP) of Sildenafil citrate. This 
method obeys Beer-Lambert’s law in concentration range of 5-30 µg/mL and 10-80 
µg/mL for Sildenafil Citrate and Aspirin respectively. Co-efficient of correlation 
were found to be 0.998 for both the drugs. The % RSD were not more than 2.0 % 
which indicates good intermediate precision. The values LOD and LOQ were 
0.588µg/mL and 1.782µg/ml for Sildenafil Citrate and 1.08µg/ml and 3.27µg/ml for 
Aspirin respectively. Percentage estimation of Sildenafil Citrate and Aspirin in 
tablet dosage form were found to be 101.00 % and 99.47% respectively.[19] 
Anusha. G et al 2012 a simple, sensitive, accurate, precise and eco-friendly 
UV spectrosphotometric method for sildenafil citrate was developed. In the present 
investigation, a 2.0 M sodium benzoate solution was employed as hydrotropic 
solubilizing agent to solubilize poorly water-soluble drug sildenafil citrate for its 
spectrophotometric analysis. Sildenafil citrate showed λ‐max at 306 nm and beer’s 
law was obeyed in the concentration range of 10 – 50 µg/ml. The results of analysis 
have been validated statistically and by recovery studies.[23] 
Anuruddha P et al 2012 was described a One simple, economical, precise 
and accurate method is described for the simultaneous determination of Dapoxetine 
and Sildenafil in combined tablet dosage form. The method is Absorption Corrected 
Method. The amplitudes at 237.54 nm and 325.92 nm in the Absorption Corrected 
Method were selected to determine DPT and SL, respectively in combined 
formulation. The method was validated by following the analytical performance 
parameters suggested by the International Conference on Harmonization (ICH). All 
validation parameters were within the acceptable range. Under experimental 
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conditions described, calibration curve, assay of tablets and recovery studies were 
performed. A critical evaluation of proposed method was performed by statistical 
analysis of data where slope, intercept, correlation coefficient is shown in Table (1). 
As per the ICH guidelines, the method validation parameters checked. Beer’s law is 
obeyed in the concentration range of 5-25 µg/ml for DPT and 8-40 µg/ml for SL by 
the given method. [12] 
Yogesh Babu et al 2014 has been developed and validated a simple, rapid, 
selective and reproducible RPHPLC method for the Analysis of Tadalafil in Bulk, 
tablets and In-Vitro Dissolution Samples. Analysis was performed on an Agilent, 
EclipseC18 column (150 mm × 4.6 mm, 5 µm) with the mobile phase consisting of 
ammonium acetate (10 mM):methanol (35:65v/v) at a flow rate of 1.0 mL/min. UV 
detection was performed at 280 nm and the retention time for TDL was 4.6 minutes. 
The dissolution media composed of 0.5% SLS, using USP II (Paddle) Dissolution 
apparatus, at 50 RPM and temperature maintained 37.0 ± 0.5  C. The method was 
validated according to ICH guidelines. The method was validated for specificity, 
accuracy, precision, ruggedness, limit of quantification, limit of detection and 
linearity. The system suitability parameters, such as , tailing factor, theoretical plate 
and relative standard deviation (RSD) for assay of five standard replicates, were 
well within the limits. The results of the studies showed that the proposed RP-HPLC 
method is simple, rapid, precise and accurate. Hence the method can be used for the 
routine Dissolution Profiling of Tadalafil as well as its assay in bulk and tablets .[20] 
  Awofisayo. O.S et al 2010 was done a work on the development of basic 
tests for sildenafil citrate (drug substance) and sildenafil citrate tablet (dosage form). 
The Basic Tests encompass physical observation, melting characteristics, colour and 
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other test reactions for the drug substance and the dosage form. These tests are 
supplemented with thin layer chromatography. The test tube identification reactions 
were carried out to demonstrate the presence of the phenyl ether and sulphonamide 
functional groups as well as the N substituted piperazine and pyrimidine rings on the 
molecule. The presence of sulphur and nitrogen in the drug moiety were also 
confirmed. The Rf values obtained from the chromatograms using three different 
solvent systems were found to be approximately same for sildenafil in the extracted 
form and the powdered tablet. A summary of test result for sildenafil citrate and 
sildenafil citrate tablet is presented that could be of use in quick verification of the 
identity of the drug.[21] 
Graziano.S et al 2014 Sildenafil citrate (Viagra®) is a vasoactive agent 
available worldwide since 1998 for the treatment of male erectile dysfunction. It is a 
selective phosphodiesterase type 5-enzyme inhibitor able to potentiate the downstream 
effects of nitric oxide on smooth muscle relaxation and vasodilation through its effects 
on the cyclic guanosine monophosphate (c-GMP) pathway in the erectile tissue of the 
penis. When sildenafil is orally administered, it is rapidly absorbed with a maximum 
plasma concentration achieved within 1 h and has a terminal half-life of between 3 to 
6 h. The drug is extensively and rapidly metabolized by the liver, primarily by the 
CYP3A4 enzyme. Although the drug is well tolerated, specific adverse events have 
been observed, like flushing, headaches, dyspepsia, and visual disturbances. Liver 
toxicity related to sildenafil consumption has been considered a very rare event. 
However, in the last decade, some cases of sildenafil-associated hepatotoxicity have 
been reported. Furthermore, some hepatic intoxications have been reported after the 
intake of “natural” or “herbal” aphrodisiac supplements sold through Internet, sex 
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shops, social media, and by word-of-mouth found to contain sildenafil and other 
phosphodiesterase type 5 (PDE-5) inhibitors. Studies investigating a possible link 
between sildenafil use and liver damage are limited, and the underlying mechanism 
responsible for hepatotoxicity is still missing. Studies in animals evidence that the 
hematopoietic function of the liver may have severely been affected as a result of a 
probable toxic effect of sildenafil. Here, the studies reporting liver toxicity by 
sildenafil in humans and in animals are reported and discussed.[22]      
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3. AIM AND OBJECTIVE OF THE WORK 
The drug analysis plays an important role in all aspects regarding the drug 
right the development to the therapeutic use of the drug. Industries manufacturing 
pharmaceutical must ensure that the raw material used and the final product obtained 
meets the required specification to fulfill this purpose they rely upon quantitative 
chemical analysis. 
The Literature survey indicates that a very few methods were developed for 
the estimation of sildenafil citrate by RP-HPLC and UV in bulk and tablet dosage 
form. So an attempt was made to develop a new RP-HPLC method for sildenafil 
citrate in soft gelatin capsules which is more reliable, economical and flexible. 
The objective of the present work is to develop a new method of estimation 
for sildenafil citrate in soft gelatin capsules by RP-HPLC method. So an attempt was 
made to develop and validate a simple, precise, accurate, linear and rapid RP-HPLC 
method as per ICH guidelines for the estimation of sildenafil citrate and to apply the 
developed method to determine the validation of compounds. 
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4. PLAN OF WORK 
1. Literature survey. 
2. Selection of drug sample. 
3. Procurement of drug &other chemicals 
4. UV-Visible spectrophotometry- wavelength selection 
5. HPLC method development 
• Selection of preliminary HPLC conditions 
• Selection of mobile phase 
• Selection on column 
• Analysis of laboratory mixture (standard) 
The steps in method development will be as follows- 
• To obtain thorough knowledge of Practical RP-HPLC method. 
• To establish the initial chromatographic conditions for method. 
• To perform assay for sildenafil citrate. 
• To  validate  the  developed  method  a  per  the  Q2  specifications  of  ICH 
guidelines. 
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1) Specificity  
2) Linearity and Range 
3) Precision 
4) Accuracy 
5) Ruggedness 
6) Limit of detection 
7) Limit of quantitation  
8) Selectivity 
Chapter 5 Drug Profile 
Dept. of Pharmaceutical Analysis 32 JKK Nattraja College of Pharmacy 
5. DRUG PROFILE 
 
Name : sildenafil citrate[24-32] 
 
Chemical structure  
 
 
 
Chemical Formula    : C28 H38 N6 O11 S 
IUPAC name    : 5 -[2-ethoxy-5-(4 methyl piperazinylsulphonyl) 
  Phenyl]-1-methyl-3-n-propyl-1,6-dihydro  
  7H-pyrazolo[4,3-d] pyrimidin-7-one citrate 
Molecular weight : 474.5764g/mol 
Description : Blue-coloured oval-shaped soft gelatine capsule 
Solubility :   Soluble in water, ethanol and methanol      
Melting point   : 187ºC to 189ºC 
Drug category : phosphodiesterase type 5 inhibitor 
Mechanism of action : When sexual stimulation causes local release of ON 
  Inhibitor of PDE5 by sildenafil citrate increased 
  levels of sildenafil causes increased levels of Cgmp 
  in  the corpus cavernosum. Sildenafil at recommeded   
  doses has no effect in the absence of  stimulation. 
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Pharmacokinetics 
Bioavailability : Approximately 41%  bioavailability orally 
Metabolism : Sildenafil appears to be completely metabolized 
  in the liver to 16 metabolites. Its metabolism is  
  mediated mainly by cytochrome P450 microsomal     
  isozymes 3A4 (major route) and 2C9 (minor route). 
Half life : Approximately 4 h 
Excretion : About 80% of an oral dose is metabolized and     
  excreted in the feces, and about 13% is excreted in     
  the urine. 
Dosage form    : Capsule  
Route   :  Oral 
Medical uses : Sildenafil is used to treat high blood pressure in the  
  lungs (pulmonary hypertension). It works by relaxing  
  and widening the blood vessels in your lungs which  
  allows the blood to flow more easily. Decreasing high  
  blood pressure in the lungs allows your heart and lungs  
  to work better and improves your ability to exercise. 
ADVERSE EFFECTS : Dizziness, lightheadedness, headache, flushing, 
  stomach upset, nosebleeds, trouble sleeping, or 
  swollen hands/ankles/feet (edema) may occur. Vision 
  changes such as increased sensitivity to light, blurred 
  vision, or trouble telling blue and green colors apart 
  may also occur. If any of these effects persist or 
  worsen, tell your doctor or pharmacist promptly. 
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6. MATERIALS AND INSTRUMENT USED 
CHEMICAL AND SOLVENTS USED: 
S. No. Name Grade Make Lot Number Purity 
01 Ammonium Acetate – AR grade AR Rankem P14G102236 97.5% 
02 Acetonitrile - HPLC grade HPLC Finar 140181013EO 99.80 
03 Potassium Hydroxide AR Rankem J038H10 85.0% 
04 HPLC  water AN WATER 
 
COLUMN USED: 
S. 
No. 
Make Column Name ID Serial No. 
01 Waters Reliant 
C18, 15 cm x 4.6mm, 
5 µm 
AD/LCCN/079 281I3416413863 
02 Waters Reliant 
C18, 15 cm x 4.6mm, 
5 µm 
AD/LCCN/050 276I3400214059 
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SAMPLE USED: 
Product name 
Batch 
number 
Packing 
details 
Mfg. 
Date 
Exp. 
Date 
Sildenafil Citrate Soft gelatin 
Capsules 50 mg 
SCC - 501 Blister pack  10/2015 09/2018 
 
WORKING STANDARD, PLACEBO USED: 
S.No. Name WS code Purity Valid Up to 
01 
Sildenafil Citrate  
Working Standard 
CP2WS/058/001 99.02 % June-2016 
02 Placebo SCC-501P Not Applicable 
 
INSTRUMENTS USED: 
S.No. Name Make & Model ID Date of Calibration 
Due date of 
Calibration 
01 
Analytical 
Weighing 
Balance 
Mettler 
Toledo XS105 
AD/INS/001 Daily calibration 
02 HPLC 
Agilent 
1260 & 1290 
series 
AD/INS/030 07.10.2015 02.04.2016 
AD/INS/031 07.10.2015 02.04.2016 
03 Sonicator PCI India AD/INS/016 Not Applicable  
04 pH Meter Hanna AD/INS/035 Daily calibration 
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7. METHOD DEVELOPMENT AND VALIDATION 
SOLUBILITY: 
According to literature review collected sildenafil citrate are freely soluble in 
water, methanol, ethanol, DMSO and DMF. The solubility was checked and  finally 
ammonium acetate  buffer was chosen for present work. 
SELECTION OF CHROMATOGRAPHIC METHOD FOR SEPARATION: 
Selection of the method depends upon the nature of sample (ionic/ ionisable/ 
neutral), its molecular weight and solubility. Most of the drugs are polar in nature 
and hence reversed phase HPLC is preferred over the normal phase HPLC method. 
The drug combinations concerned for the present study are also polar. Hence 
reversed phase HPLC was selected for separation of the drug combination because 
of its suitability. 
SELECTION OF DETECTION OF WAVELENGTH (λ max): 
Selection  of  detection  of  wavelength  is  a  critical  step  in  the  analytical 
method.  The spectrum of diluted solutions was scanned over the range of 200 – 400 
nm in spectrum mode.  
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UV SPECTRA OF SILDENAFIL CITRATE  
 
TRIAL 1 
Column : waters reliant C18, 15 cm x 4.6 mm, 5 µm  
Flow Rate : 1.0 mL/minute 
Pump mode : Isocratic  
Detector wavelength             : 240 nm 
Injection volume : 20 µL 
Column Temperature : 25.0˚C 
Mobile phase composition : Phosphate buffer:  Acetonitrile 1:1% v/v 
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TRIAL 2 
Column : C18, 15 cm x 4.6 mm, 5 µm  
Flow Rate : 1.0 mL/minute 
Pump mode : Isocratic  
Detector wavelength : 240 nm 
Injection volume : 20 µL 
Column Temperature : 25.0˚C 
Mobile phase composition : Ammonium acetate: Acetonitrile 1.5:0.5% v/v 
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Optimized Chromatographic conditions: 
Column : C18, 15 cm x 4.6 mm, 5 µm  
Flow Rate : 1.0 mL/minute 
Pump mode : Isocratic  
Detector wavelength     : 240 nm 
Injection volume : 20 µL 
Column Temperature : 25.0˚C 
Mobile phase composition : Ammonium acetate buffer :  Acetonitrile 1:1% v/v 
Methodology adopted 
 Mobile phase selection 
 Preparation of buffer solution 
 Preparation of mobile phase 
 Preparation of diluent 
 Preparation of standard stock solution 
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 Preparation of standard solution 
 Preparation of sample solution 
 Setting the instrumental parameters before performing the analysis for 
1.   Detector 
2.   Pump 
 Development of chromatogram and determination of retention time. 
Selection of mobile phase: 
The mobile phase system consisting of ammonium acetate and acetonitrile in 
the ratio of 1:1v/v was found to be effective in the separation of sildenafil citrate in 
pure form as well as in dosage forms. 
MOBILE PHASE PREPARATION:   
Preparation of 5M Potassium hydroxide solution: 
 Weigh and dissolve 28.0 g of Potassium hydroxide in a 100 mL volumetric 
flask and dilute to volume with purified water.  
Preparation of 0.2M Ammonium acetate Buffer: 
 Weigh and dissolve 15.42 g of ammonium acetate in a 1000 mL volumetric 
flask, and dilute up to the volume with purified water. Adjust the pH  to 7.00 with 
5M Potassium hydroxide solution. 
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Preparation of Mobile Phase: 
  Prepare a mixture 500 volume of Ammonium acetate Buffer and 500 volume 
of Acetonitrile, mix well. Filter the solution through 0.45 µm nylon filter and 
sonicate for 10 minutes. 
Preparation of Diluent: 
Mobile phase 
Procedure for preparation of analytical solution: 
Preparation of standard solution (50.0 mcg /mL of Sildenafil Citrate): 
  Weigh accurately 50 mg of Sildenafil Citrate working standard and transfer 
into 100 mL volumetric flask, add 60 mL of mobile phase and sonicate for 5 minutes 
to dissolve. Cool and dilute up to the volume with mobile phase and mix well. 
Transfer 5 mL of the above solution through pipette into 50 mL volumetric flask and 
dilute up to the volume with mobile phase . Filter the solution through 0.45 µm 
nylon filter and collect the solution in an HPLC vial after discarding about the first 2 
mL of the filtrate. 
Preparation of sample solution for 50 mg (50.0 mcg/mL of Sildenafil Citrate): 
  Accurately weigh and transfer 5 soft gelatin capsules (equivalent to 250 mg 
of Sildenafil Citrate) into 250 mL volumetric flask. Add about 25 mL of water and 
sonicate for 10 minutes to disperse the capsules shell. Add about 120 mL of mobile 
phase and sonicate for 15 minutes to dissolve. Cool and dilute up to the volume with 
mobile phases and mix well. Transfer 5 mL of the above solution through pipette 
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into 100 mL volumetric flask and dilute up to the volume with mobile phases and 
mix. Filter the solution through 0.45 µm nylon filter and collect the solution in an 
HPLC vial after discarding about the first 2 mL of the filtrate. 
METHOD VALIDATION 
Validation of analytical method is a process to establish that the performance 
characteristics of the developed method meet the requirement of the intended 
analytical application.[34-53]  
SYSTEM SUITABILITY PARAMETERS 
System suitability is the test to ensure that the methods can generate results 
of acceptable accuracy and precision.  
Standard solutions of ranitidine Hcl   were prepared as per test method and 
five replicate injections were made to study system suitability parameters. 
Parameters studied Tailing Factor. 
Number of theoretical plates (N). Retention time. 
Relative standard deviation. 
Typical analytical parameters used in method validation include 
1.   Specificity 
2.   Linearity and Range 
3.   Precision 
4.   Accuracy 
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5.   Ruggedness 
6.   Limit of detection 
7.   Limit of quantitation  
8.   Selectivity 
SPECIFICITY 
The  specificity of  the  method  can  be  defined  as  the  ability to  measure 
accurately the concentration of an analyte in the presence of all other sample 
materials.  
Procedure: 
 Inject the blank, placebo, standard and sample preparations based on 
“Injection sequence” detailed below and measure the corresponding area. 
Injection sequence: 
   Particulars Number of Injection 
Blank  1 
Placebo preparation 1 
Standard preparation 5 
Sample preparation 2 
Bracketing standard 1 
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Acceptance criteria: 
  No any peak should be obtained in the retention time of Sildenafil Citrate 
from the blank and placebo chromatograms. 
LINEARITY AND RANGE 
Linearity is  the  measure  of  how  well  a  calibration  plot  of  response  Vs 
concentration approximates a straight line. Linearity can be assessed by performing 
the single measurement s at several analyte concentrations. The data are then 
processed using a linear least square regression. The resulting plot slope, intercept 
and correlation coefficient provide the desired information on linearity.  
  Ability to obtain test results which are directly proportional to the 
concentration of analyte. For an establishment of the linearity 60%, 80%, 100%, 
120%, and 160% of standard and sample concentrations shall be used. 
Preparation of Linearity from standard: 
Standard stock solution (500 mcg/mL of Sildenafil Citrate): 
  Weigh accurately about 50 mg of Sildenafil Citrate working standard and 
transfer into 100 mL volumetric flask, add 60 mL of mobile phase and sonicate for 5 
minutes to dissolve. Cool and dilute up to the volume with mobile phase and mix 
well.  
60 % Linearity standard concentration (30.0 mcg/mL of Sildenafil Citrate): 
  Transfer 3.0 mL of above standard stock solution through pipette  into a 50 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
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solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
80 % Linearity standard concentration (40.0 mcg/mL of Sildenafil Citrate): 
  Transfer 4.0 mL of above standard stock solution through pipette  into a 50 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about first 2 mL of filtrate. 
100 % Linearity standard concentration (50.0 mcg/mL of Sildenafil Citrate):  
  Transfer 5.0 mL of above standard stock solution through pipette  into a 50 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
120 % Linearity standard concentration (60.0 mcg/mL of Sildenafil Citrate): 
  Transfer 6.0 mL of above standard stock solution through pipette  into a 50 
mL volumetric flask and dilute up to the volume with mobile phase and mix. Filter 
the solution through 0.45 µm nylon membrane filter and collect the solution in an 
HPLC vial after discarding about the first 2 mL of the filtrate. 
160 % Linearity standard concentration (80.0 mcg/mL of Sildenafil Citrate): 
  Transfer 8.0 mL of above standard stock solution through pipette into a 50 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
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solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
Preparation of Linearity solution from Sample: 
Sample stock solution (1000 mcg/mL of Sildenafil Citrate): 
  Accurately weigh and transfer 5 soft gelatin capsules of Sildenafil Citrate  
sample (equivalent to 250 mg of Sildenafil Citrate) into 250 mL volumetric flask. 
Add about 25 mL of water and sonicate for 10 minutes to disperse the capsules shell. 
Add about 120 mL of mobile phase and sonicate for 15 minutes to dissolve. Cool 
and dilute up to the volume with mobile phases and mix well.  
60 % Linearity sample concentration (30.0 mcg/mL of Sildenafil Citrate): 
  Transfer 3.0 mL of above Sample stock solution through pipette into a 100 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
80 % Linearity sample concentration (40.0 mcg/mL of Sildenafil Citrate): 
  Transfer 4.0 mL of above Sample stock solution through pipette into a 100 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
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100 % Linearity sample concentration (50.0 mcg/mL of Sildenafil Citrate): 
  Transfer 5.0 mL of above Sample stock solution through pipette into a 100 
mL volumetric flask and dilute up to the volume with mobile phase and mix. Filter 
the solution through 0.45 µm nylon membrane filter and collect the solution in an 
HPLC vial after discarding about the first 2 mL of the filtrate. 
120 % Linearity sample concentration (60.0 mcg/mL of Sildenafil Citrate): 
  Transfer 6.0 mL of above Sample stock solution through pipette into a 100 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate. 
160 % Linearity sample concentration (80.0 mcg/mL of Sildenafil Citrate): 
  Transfer 8.0 mL of above Sample stock solution through pipette into a 100 mL 
volumetric flask and dilute up to the volume with mobile phase and mix. Filter the 
solution through 0.45 µm nylon membrane filter and collect the solution in an HPLC 
vial after discarding about the first 2 mL of the filtrate.    
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Injection sequence: 
                 
Acceptance criteria: 
 Correlation co-efficient between concentrations and its area should be more 
than 0.998. 
PRECISION 
  The precision of an analytical procedure expresses the closeness of 
agreement between a series of measurements under the prescribed conditions. 
SYSTEM PRECISION: 
  Determines the closeness of agreement of the same homogenous standard 
preparations under     the prescribe conditions.   
Procedure:   
Inject the blank, standard preparations based on “Injection sequence” 
Different Linearity Standard and Sample preparations Number of Injection 
Blank 1 
Standard preparation 5 
60 % Linearity standard and sample concentration 2 
80 % Linearity standard and sample concentration 2 
100 % Linearity standard and sample concentration 2 
120 % Linearity standard and sample concentration 2 
160 % Linearity standard and sample concentration 2 
Bracketing Standard 1 
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detailed below and measure the corresponding area. 
Injection sequence: 
                                                         
 
    
System Suitability requirement:  
  Report the system suitability requirement A to C as mentioned in the method 
of analysis in the step no.: 5.0 
Acceptance criteria: 
 The Tailing factor of the peak due to Sildenafil Citrate obtained from five 
replicates standard solution injections should be not more than 2.0. 
 Theoretical plates of the peak obtained for five replicates standard solution 
injections of Sildenafil Citrate should be not less than 2000. 
 The relative standard deviation of the area obtained for Five replicate standard 
solution of Sildenafil Citrate should be not more than 2.0%. 
 The relative standard deviation of the retention time obtained for five replicate 
standard solution of Sildenafil Citrate should be not more than 1.0%. 
Particulars Number of Injection 
Blank  1 
Standard preparation 5 
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A) SYSTEM PRECISION  
METHOD PRECISION (REPEATABILITY): 
  Determines the closeness of agreement of the same homogenous sample 
under the prescribe conditions. Performing assay of sildenafil citrate Soft gelatin 
Capsules 50 mg a minimum of six sample preparations from a single batch shall be 
made and analyze separately. 
Procedure:   
  Inject the blank, standard and sample preparations based on “Injection 
sequence” detailed below and measure the corresponding area. 
Injection sequence:  
                                                         
 
Acceptance criteria: 
 Assay obtained for each six sample preparations should be between 90.0 and 
110.0%. 
 The RSD obtained for the assay results for six sample preparations should be 
not more than 2.0 %.    
Particulars Number of Injection 
Blank  1 
Standard preparation 5 
Sample preparations – 1,2,3,4,5,6 2 
Bracketing standard 1 
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METHOD PRECISION (REPEATABILITY):  
 The method precision was determined by preparing six sample solutions of 
Sildenafil Citrate from Sildenafil Citrate Soft gelatin Capsules 50 mg as per the 
procedure included in the protocol. 
ACCURACY  
Accuracy is defined as closeness of measured value to the true value The 
accuracy of an analytical procedure expresses the closeness of agreement between 
the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. 
Preparation of analytical solution: 
Preparation of standard solution (50.0 mcg /mL of Sildenafil Citrate): 
 Weigh accurately about 50 mg of Sildenafil Citrate working standard and 
transfer into 100 mL volumetric flask, add 60 mL of mobile phase and sonicate for 5 
minutes to dissolve. Cool and dilute up to the volume with mobile phase and mix 
well. Transfer 5 mL of the above solution through pipette into 50 mL volumetric 
flask and dilute up to the volume with mobile phase and mix well. Filter the solution 
through 0.45 µm nylon filter and collect the solution in an HPLC vial after 
discarding about the first 2 mL of the filtrate. 
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Placebo spiked with 50 % standard preparation (25.0 mcg/mL of Sildenafil 
Citrate): 
  Weigh accurately 1 Sildenafil Citrate soft gelatin capsules 100 mg Placebo 
and 50 mg of Sildenafil Citrate Working standard and transfer into 200 mL 
volumetric flask. Add about 25 mL of water and sonicate for 10 minutes to disperse 
the capsules shell. Add about 100 mL of mobile phase and sonicate for 15 minutes 
to dissolve. Cool and dilute up to the volume with mobile phase and mix well. 
Transfer 5 mL of the above solution through pipette into 50 mL volumetric flask and 
dilute up to the volume with mobile phase and mix. Filter the solution through 0.45 
µm nylon filter and collect the solution in an HPLC vial after discarding about first 2 
mL of filtrate. Prepare the sample preparation in triplicate. 
Placebo spiked with 100 % standard preparation (50.0 mcg/mL of Sildenafil 
Citrate): 
  Weigh accurately 1 Sildenafil Citrate soft gelatin capsules 100 mg Placebo 
and 100 mg of Sildenafil Citrate Working standard and transfer into 200 mL 
volumetric flask. Add about 25 mL of water and sonicate for 10 minutes to disperse 
the capsules shell. Add about 100 mL of mobile phase and sonicate for 15 minutes 
to dissolve. Cool and dilute up to the volume with mobile phase and mix well. 
Transfer 5 mL of the above solution through pipette into 50 mL volumetric flask and 
dilute up to the volume with mobile phase and mix. Filter the solution through 0.45 
µm nylon filter and collect the solution in an HPLC vial after discarding about first 2 
mL of filtrate. Prepare the sample preparation in triplicate. 
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Placebo spiked with 150 % standard preparation (75.0 mcg/mL of Sildenafil 
Citrate): 
  Weigh accurately 1 Sildenafil Citrate soft gelatin capsules 100 mg Placebo 
and 150 mg of Sildenafil Citrate Working standard and transfer into 200 mL 
volumetric flask. Add about 25 mL of water and sonicate for 10 minutes to disperse 
the capsules shell. Add about 100 mL of mobile phase and sonicate for 15 minutes 
to dissolve. Cool and dilute up to the volume with mobile phase and mix well. 
Transfer 5 mL of the above solution through pipette into 50 mL volumetric flask and 
dilute up to the volume with mobile phase and mix. Filter the solution through 0.45 
µm nylon filter and collect the solution in an HPLC vial after discarding about first 2 
mL of filtrate. Prepare the sample preparation in triplicate. 
Procedure: 
 Inject the blank, standard and placebo spiked standard preparations based on 
“Injection sequence” detailed below and measure the corresponding area. 
Injection sequence Table:                                                        
Particulars 
No.  of 
injections 
Blank 1 
Standard preparation  5 
Placebo spiked standard solution 50% - preparations 1, 2 & 3 Each 3 
Placebo spiked standard solution 100% - preparations 1, 2 & 3 Each 3 
Placebo spiked standard solution 150% - preparations 1, 2 & 3 Each 3 
Bracketing Standard 1 
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Calculations for Sildenafil Citrate accuracy 
Step 1: Standard added in mg (Working standard solution) 
  Standard wt in mg          5           
------------------------- X --------       
          100                        50 
Step 2: Placebo spiked standard added in mg at 100% 
Wt of spiked standard in mg          5   
----------------------------------    X ------ 
               200                                  50                      
Step 3: Placebo spiked standard recovered in mg 
Placebo spiked standard area X standard added in mg (Working standard solution) 
---------------------------------------------------------------------------------------------- 
Average area of working standard solution 
Step 4: Recovery in percentage 
  Placebo spiked standard recovered in mg 
-----------------------------------------------------     X 100 
    Placebo spiked standard added in mg 
System Suitability requirement:  
 Report the system suitability requirement A, B and C as mentioned in the 
method of analysis in the step No.: 5.0. 
Acceptance criteria: 
 In each concentration, the sildenafil citrate working standard spiked with 
placebo should be recovered between 98.0 % and 102.0 %. 
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ROBUSTNESS: 
The Robustness for the analytical procedure expresses a measure of its 
capacity to remain unaffected by small, but deliberate variations in method 
parameters and provides an indication of its reliability during analysis 
Procedure: 
Working standard solutions and working sample solution were prepared by 
different analyst on different days. Solutions were injected as per the test method 
and chromatograms were recorded. 
Inject the blank, standard and sample solution preparations based on 
“Injection sequence” detailed below and measure the corresponding area. 
Injection sequence: 
                                                    
 
 
 
Acceptance criteria: 
 Assay obtained for each six sample preparations should be between 90.0 and 
110.0 %. 
 The RSD obtained for the assay results for six sample preparations should be 
not more    than 2.0 %.    
Particulars Number of Injection 
Blank  1 
Standard preparation 5 
Sample preparations – 1,2,3,4,5,6 2 
Bracketing standard 1 
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a. INTERMEDIATE PRECISION-(RUGGEDNESS) : 
The Intermediate precision was determined by preparing six sample solutions 
of Sildenafil Citrate Soft gelatin Capsules 50 mg by a different analyst. 
Robustness  
Robustness of an analytical method is measure of its capacity to remain 
unaffected by small but deliberate variation in method parameters. It provides 
information about the reliability of method. 
DETERMINATION: 
The robustness of an analytical method is determined by analysis of aliquots 
of homogenous lots by differing physical parameters like flow rate and column 
temperature. 
Change in flow rate plus (1.2 mL/minute): 
For Chromatographic conditions, follow the method of analysis given in the 
step No.: 5.0 except by changing the flow to 1.2 mL / minute instead of 1.0 mL / 
minute. 
Change in flow rate minus (0.8 mL/minute): 
For Chromatographic conditions, follow the method of analysis given in the 
step No.: 5.0 except by changing the flow to 0.8 mL / minute instead of 1.0 mL / 
minute. 
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Change in wavelength plus (242 nm): 
For Chromatographic conditions, follow the method of analysis given in the 
step No.: 5.0 except   by changing the wavelength to 242 nm instead of 240 nm. 
Change in wavelength minus (238 nm): 
For Chromatographic conditions, follow the method of analysis given in the 
step No.: 5.0 except    by changing the wavelength to 238 nm instead of 240 nm. 
System Suitability requirement: 
Report the system suitability requirement A, B and C as mentioned in the 
method of analysis given in the step No.: 5.0. 
Acceptance criteria: 
 Assay obtained for each robustness parameter should be between 90.0 and 
110.0%. 
 The combined RSD obtained for the assay result of an each robustness parameter 
and six assay results of method precision should be not more than 2.0 %.    
ROBUSTNESS 
  A deliberate plus and minus changes in the analytical method parameters 
such as in wavelength, and flow rate was altered and the assay analytical study done 
as per the protocol. 
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STABILITY OF ANALYTICAL SOLUTIONS: 
Solutions to be used in the analytical method should be analyzed for the 
study of their stability. This study should be performed by injecting standard 
solution and sample solution at probable time points, and minimum not less than 24 
hours shall be studied. 
Note:  
 Maintain the chromatographic conditions and solutions preparation as per the 
procedure given in method of analysis which is described under section No.:5.0 
and injections sequence for solution stability study is given in below table. 
 The maximum time for inject able usage of standard and sample solution is 
absolutely depends on the X Hours of solutions stability studied. 
Injection sequence: 
                                                   Table No. 24 
Particulars Number of Injections 
Blank  (0 Hour) 1 
Standard preparation (0 Hour) 1 
Sample preparation  (0 Hour) 1 
Blank  (X Hours) 1 
Standard preparation (X Hours) 1 
Sample preparation  (X Hours) 1 
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Acceptance criteria: 
  Cumulative % RSD for area obtained between initial time point and various 
probable intervals time points should be not more than 2.0 %. 
STABILITY OF ANALYTICAL SOLUTIONS: 
  Standard and sample solutions to be used in the analytical method are 
scrutinized for their solution’s stability. This study was performed by injecting 
standard and sample solution for the period of 24 hours.  
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8. CHROMOTOGRAMS 
 
SPECIFICITY (blank , standard & sample) 
 
Chromatogram No : 8.1 Blank 
 
 
 
Chromatogram No : 8.2 placebo 
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Chromatogram No : 8.3 Standard 
 
 
Chromatogram No : 8.4 Sample  
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LINEARITY 
Standard 
Chromatogram No:8.5 Linearity 60% 
 
Chromatogram No:8.6 linearity 80% 
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Chromatogram No : 8.7 Linearity 100%  
 
Chromatogram No : 8.8 Linearity 120% 
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Chromatogram No : 8.9 Linearity 160% Standard 
 
Chromatogram No. : 8.10 Linearity 160% 
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Sample 
Chromatogram No : 8.11 Linearity 60% 
 
Chromatogram No. : 8.12 Linearity 100% 
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Chromatogram No : 8.13 
Linearity 120% 
 
Chromatogram No : 8.14  
Linearity 160% Sample 
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SYSTEM PRECISION  
Chromatogram No : 8.15 
  
 
Chromatogram No : 8.16 
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Chromatogram No : 8.17 
 
 
Chromatogram No : 8.18 
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Chromatogram No : 8.19 
 
 
METHOD PRECISION 
Chromatogram No : 8.20 Sample 
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Chromatogram No : 8.21 
 
Chromatogram No : 8.22 
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Chromatogram No : 8.23 
 
Chromatogram No : 8.24 
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Chromatogram No : 8.25 
 
ACCURACY 
Chromatogram No : 8.26 
Accuracy 50% Preparation 1 
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Chromatogram No : 8.27 
Accuracy 50% Preparation 2 
 
 
Chromatogram No : 8.28 
Accuracy 50% Preparation 3 
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Chromatogram No : 8.29 
Accuracy100% Preparation 1 
 
 
Chromatogram No : 8.30 
Accuracy 100% Preparation 
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Chromatogram No : 8.31 
Accuracy 100% Preparation 3 
 
 
Chromatogram No : 8.32 
Accuracy 150% Preparation 1 
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Chromatogram No : 8.33 
Accuracy 150% preparation 2 
 
Chromatogram No : 8.34 
Accuracy 150% Preparation  3 
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Chromatogram No : 8.35 
RUGGEDNESS (Inter mediate precision) 
Sample50mg Preparation 1 
 
Chromatogram No : 8.36 
Sample 50 Mg Preparation 2 
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Chromatogram No : 8.37 
Sample 50 mg Preparation  2 
 
Chromatogram No : 8.38 
Sample 50mg Preparation 2 
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Chromatogram No : 8.39 
Sample 50 mg reparation 3 
 
Chromatogram No : 8.40 
Sample 50mg preparation 3 
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Chromatogram No : 8.41 
Sample 50 mg Preparation 4 
 
Chromatogram No : 8.42 
Sample 50mg Preparation 4 
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Chromatogram No. : 8.43 
Sample 50 mg Preparation 5 
 
Chromatogram No : 8.44 
Sample 50mg Preparation 5 
 
Chapter 8 Chromatograms 
Dept. of Pharmaceutical Analysis 82 JKK Nattraja College of Pharmacy 
Chromatogram No : 8.45 
Sample 50mg Preparation 6 
 
Chromatogram No : 8.46 
Sample 50mg Preparation 6 
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 ROBUSTNESS 
Chromatogram No : 8.47 
Sample 
Change in flow rate (0.8 ml)-1 
 
Sample Chromatogram No : 8.48 
Change in Flow Rate (0.8ml)-2 
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Chromatogram No : 8.49 Flow Rate Plus 
Sample Change in Flow Rate (1.2ml) 
 
 
Chromatogram No : 8.50 
Change in flow rate (1.2ml) 
 
 
Chapter 8 Chromatograms 
Dept. of Pharmaceutical Analysis 85 JKK Nattraja College of Pharmacy 
Chromatogram No : 8.51 
Change in flow rate (1.2ml) 
 
 
Chromatogram No : 8.52 
Sample change in wave length (238nm) 
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Chromatogram No : 8.53 
Sample change in wave length (238nm)  
 
 
Chromatogram No : 8.54 
Sample change in wave length(238nm) 
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Chromatogram No : 8.55 
Robusness wavelength plus (242 nm) Sample replicate No 1 
 
 
 
Chromatogram No : 8.56 
Sample Replicate No. 2 
 
 
Chapter 8 Chromatograms 
Dept. of Pharmaceutical Analysis 88 JKK Nattraja College of Pharmacy 
Chromatogram No : 8.57 
Sample Replicate No. 3 
 
 
STABILITY STUDY: 
STANDARD  0, 3, 6, 9, 12, 15, 18, 21, 24,   HOURS  
Chromatogram No : 8.58 
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Chromatogram No : 8.59 
 
Chromatogram No : 8.60 
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Chromatogram No : 8.61 
 
Chromatogram No : 8.62 
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Chromatogram No : 8.63 
 
 
Chromatogram No : 8.64 
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Chromatogram No : 8.65 
 
Chromatogram No : 8.66 
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STABILITY STUDY: 
SAMPLE  0, 3, 6, 9, 12, 15, 18, 21, 24 HOURS 
Chromatogram No : 8.67 
 
Chromatogram No : 8.68 
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Chromatogram No : 8.69 
 
 
Chromatogram No : 8.70 
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Chromatogram No : 8.71 
 
Chromatogram No : 8.72 
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Chromatogram No : 8.73 
 
Chromatogram No : 8.74 
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Chromatogram No : 8.75 
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9. RESULTS AND DISCUSSION 
A new isocratic reverse-phase high performance liquid chromatographic at 
was   developed   for   quantitative   determination   of sildenafil citrate soft gelatin 
capsule dosage forms. The mobile phase was used ammonium acetate and acetonitile 
in the proportion of 1:1 v/v. The chromatographic method was performed on C18, 
15 cm×4.6 mm,5µm column at a flow rate of 1.0 ml/min. Column Temperature 
was set a 25ºC and injection volume was 20µ l. 
Estimation   of sildenafil citrate soft gelatin capsule dosage form dosage 
forms by RP-HPLC method was carried out using optimized chromatographic 
conditions. The standard and sample solutions were prepared. The chromatograms 
were recorded. The peak area ratio of standard and sample solutions was calculated. 
The capsule shows percentage purity values ranging from 99.36% to 100.52%   for 
sildenafil citrate respectively. 
The method was validated according to the Q2 specifications of the ICH 
guidelines. The validated parameters were system suitability, Precision, Accuracy, 
Specificity, linearity, Ruggedness Robustness and. LOD, LOQ. 
The   resulting chromatograms exhibited retention time  at  4.5 min for  
sildenafil citrate soft gelatin caplules. The number of theoretical plates were more 
than 2000, for sildenafil citrate it was 11325 respecitively. The tailing factor was less 
than 2 that is 1.12 for sildenafil citrate.  Hence all the system suitability parameters 
were with the specified limits.  
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Specificity 
 The specificity of the method was established by injecting blank, placebo 
and standard. It was observed that there was no interference caused due to the 
placebo. The chromatogram were shown in chromatogram no : 8.1 – 8.4. 
S.No. Name of the 
solution 
Results obtained Acceptance criteria 
01 Blank 
No  peak  found in the 
retention time of sildenafil 
citrate 
No any peak should be 
found in the retention 
time of sildenafil citrate 
02 Placebo 
No  peak  found in the 
retention time of sildenafil 
citrate 
No any peak should be 
found in the retention 
time of sildenafil citrate 
 
  System suitability result passes and the results obtained for specificity are found 
within the acceptance criteria. The obtained results proved that there will not be 
blank and placebo interference in the sildenafil citrate soft gelatin capsule peak by 
this assay method. 
Linearity 
 The linearity for the drugs from concentration range of 30 - 60 and 80 µ g/ml 
was established by constructing the calibration curve with concentration on x-axis 
and peak area on y-axis with the correlation coefficient of 0.999 for the drug 
which were within specified limits. The  results were shown in Table no: 7.1 ,7.2 
and Figure no 7.1,7.2.  The chromatogram were shown in chromatogram no: 8.5-
8.14. 
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Table No 7.1: Linearity data obtained from 60 % to 160 % for Standard 
 
 Figure No 7.1: Calibration curve of standard sildenafil citrate 
 
Linearity level 
Concentration 
in % 
Concentration 
of  Sildenafil 
Citrate  
mcg/mL) 
Standard 
area -1 
Standard 
area-2 
Average 
area 
60 30 151677294 151861664 151769479 
80 40 201279288 202136838 201708063 
100 50 250885878 251145548 251015713 
120 60 303794785 304201777 303998281 
160 80 399892519 399849420 399870970 
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Table no 7.2: Linearity data obtained from 60% to 160% for Sample 
 
Figure No 7.2:  Calibration curve of sample sildenafil citrate 
 
System suitability result passes and the results obtained for linearity are 
found within the acceptance criteria. Hence it is concluded that the range of 
concentrations, 60 % to 160 % with respect to 100 % working concentration for 
assay method is linear for sildenafil citrate soft gelatin capsule. 
Linearity level 
Concentration 
in % 
Concentration of 
Sildenafil 
Citrate (mcg/mL) 
Sample 
area -1 
Sample 
area-2 
Average 
area 
60 30 158469512 159881630 159175571 
80 40 205672985 206225062 205949024 
100 50 262694385 265295848 263995117 
120 60 313842623 315675130 314758877 
160 80 413117111 413207957 413162534 
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PRECISION 
System precision  was  determined  by preparing  the  standard  solution  at 
working concentration and analysis was carried for six replicate injections. The 
percentage relative standard deviation (% RSD) was calculated for the peak areas of 
sildenafil citrate which was found to be 0.091 respectively which were within the 
acceptance criteria of not more than 2.0%. The percentage relative standard 
deviation (% RSD) was calculated for the peak retention time of sildenafil citrate 
soft gelatin which was found to be 0.003 respectively which were within the 
acceptance criteria of not more than 1.0%.  The results were presented in shown in 
Table no 7.3 and Chromatogram No. 8.15 – 8.19. All the system suitability 
parameters were well within the desirable limits, it indicates that the prescribed 
method is suitable to perform the estimation of sildenafil citrate Soft gelatin 
Capsules  Further there was no deviation in the given method  
Table No 7.3: System precision (standard solution) 
S. No. Sildenafil Citrate Retention time  
Sildenafil 
Citrate area Tailing factor  Theoretical plates  
01 4.480 252184542 1.13 11339 
02 4.487 252489103 1.10 11336 
03 4.480 252063502 1.12 11352 
04 4.480 251865543 1.11 11350 
05 4.480 252233194 1.12 11342 
Mean 4.481 252167177 1.12 11344 
Std dev 
 
0.003 229143.90 
NMT 2.0 NLT 2000 (RSD %) 0.07 0.091 
Limit NMT 1.0 % NMT 2.0 % 
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Method precision 
 Method  precision  was  determined  by  preparing  six  different  samples 
solutions from the capsules of same batch at working concentration and analysis was 
carried out for six replicate injections. The percentage relative standard deviation (% 
RSD) was calculated for the peak areas of sildenafil citrate which was found to be 
1.006 for the drug which is within the acceptance criteria of not more than 2.0%. 
These results give the assurance of method repeatability. The results were presented 
in Table no: 7.4 and shown in Chromatogram No. 8.20 – 8.25. 
Table No 7.4: Method precision results 
No. of 
Sample       
preparation 
Samples Area Results obtained 
Acceptance 
criteria Sample -1 Sample -2 Average 
Amount of 
drug present  
in mg 
 Percentage 
of drug  
01 273811226 273874982 273843104 53.62 107.24 
90
.
0%
 
-
 
11
0.
0%
 02 278804156 279439194 279121675 54.65 109.30 
03 275977625 275569282 275773454 53.99 107.98 
04 279908440 280739967 280324204 54.88 109.76 
05 275057250 275230784 275144017 53.87 107.74 
06 280151042 280056030 280103536 54.84 109.68 
 
Mean 108.62 
Std. Dev 1.093 
RSD 1.006 NMT 2.0 % 
 
System suitability parameters were well within the prescribed limits which 
revealed that the prescribed procedure is capable to perform Method precision using 
sample preparation. All the performed samples showed results between 90.0 % and 
110.0 %.The Method precision parameter complies as per In-House specification. 
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Accuracy 
Accuracy of the method was determined by performing recovery studies at 
50%, 100%, 150%. Percentage recovery sildenafil citrate were found to be % of 
recovered within  the range of 99.40 , 99.36 and 100.52  respectively which were 
within the acceptance criteria of 98 - 102% respectively. The result of accuracy were 
presented in Table No: 7.5 and shown in Chromatogram No. 8.26-8.34.  
Table No. 7.5: Accuracy Results 
Accuracy 
Level in % 
Sildenafil 
Citrate 
added 
in mg 
Sildenafil 
Citrate 
Recovered 
in mg 
% 
Recovered 
Mean of % 
Recovered  
Acceptance 
criteria  
50 
0.024895 0.024741 99.38 
99.40 
98
.
0 
%
 
-
 
10
2.
0 
%
 
0.024675 0.024614 99.75 
0.024645 0.024414 99.06 
100 
0.049795 0.049570 99.55 
99.36 0.050035 0.049681 99.29 
0.050060 0.049677 99.23 
150 
0.075125 0.075456 100.44 
100.52 0.075510 0.076233 100.96 
0.075055 0.075180 100.17 
 
System suitability result passes and the results obtained for accuracy are 
found within the acceptance criteria. Hence, it is concluded that the assay method for 
sildenafil citrate Soft gelatin Capsules 50 mg is proficient to recover between 50 % 
and 150 % of sildenafil citrate drug material when spiked in placebo. 
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Ruggedness: 
  Ruggedness was determined by performing the same assay by different 
analyst on the different days and the results were checked for the reproducibility. 
The  %RSD  was  found  to  be  1.267  sildenafil citrate which were within the 
acceptance range of not more than 2 %. The results of ruggedness were shown in 
Table No: 7.6 and Chromatogram No. 8.35-8.46. 
Table No 7.6: Intermediate Precision Results 
No. of 
Sample       
preparation 
Samples Area Results obtained 
Acceptance 
criteria Sample -1 Sample -2 Average 
Amount 
of drug 
present 
in mg 
Percentage   
of 
drug 
01 247554814 247931835 247743325 53.20 106.40 
 
90
.
0%
 
-
 
11
0.
0%
 02 245984367 247002518 246493443 52.93 105.86 
03 253501297 255339321 254420309 54.63 109.26 
04 249292157 250075032 249683595 53.62 107.24 
05 247967600 248895826 248431713 53.35 106.70 
06 253210685 253399230 253304958 54.39 108.78 
 
Mean 107.37 
Std. Dev 1.360 
RSD 1.267 NMT 2.0 % 
 
System suitability result passes and the results obtained for Intermediate 
precision are found within the acceptance criteria. Combined Intermediate precision 
results and Method precision results are meets the prescribed limit as per In-House 
specification. Hence, it is concluded that the assay method is capable to generate, 
repeatable assay results for sildenafil citrate Soft gelatin Capsules 50 mg in multiple 
preparations of a unique batch, besides by a different analyst 
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LOD and LOQ:  
The Limit of Detection (LOD) and Limit of Quantitation (LOQ) was 
determined by injecting progressively low concentrations of the standard solutions 
using the developed RP-HPLC method. The LOD is the smallest concentration of 
the  analyte  that  gives  a  measurable  response  (signal  to  noise  ratio  of  3). The 
detection limit (LOD) was found to be 0.71µ g/ml for sildenafil citrate respectively. 
The LOQ is the smallest concentration of the analyst that given a measurable 
quantity ( singnal to noise ratio of 10). The quantitation limit (LOQ) was found to be 
2.15 µg/ml for sildenafil citrate respectively. 
Robustness: 
The Robustness of the method was established changing the parameters like 
wave length and flow rate. The changes in system suitability parameters were 
within the limits which ensures that the method developed can withstand slight 
changes in the experimental conditions and produce results with good reproducibility 
and repeatability. Results were presented in Table no: 7.7-7.8 and the 
chromatogram were shown in Chromatogram No. 8.47 – 8.57. 
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Table No 7.7: System suitability results 
S.No. Parameter Name 
Sildenafil Citrate Results  
Tailing factor  
Theoretical 
Plates 
Area 
(RSD) 
01 Wavelength Plus (242 nm) 1.12 11346 0.113 
02 Wavelength Minus (238 nm) 1.12 11345 0.101 
03 Flow rate Plus (1.2 mL) 1.12 10330 0.134 
04 Flow rate Minus (0.8 mL) 1.13 12516 0.238 
Acceptance criteria NMT 2.0 NLT 2000 NMT 2.0% 
 
Table No 7.8 : Robustness results 
 S.No. Parameter Name 
Sildenafil Citrate 
Acceptance 
criteria 
Drug 
Obtained 
in mg 
Drug 
Obtained 
in % 
01 Wavelength Plus (242 nm) 54.78 109.56 
 
90
.
0%
 
-
 
11
0.
0%
 
 
02 Wavelength Minus (238 nm) 54.75 109.50 
03 Flow rate Plus (1.2 mL) 54.14 108.28 
04 Flow rate Minus (0.8 mL) 54.65 109.30 
 
System suitability result passes in all the deliberately changed methods and 
the results obtained for all deliberately changed methods are found within the 
acceptance criteria. Combined deliberately changed methods results and Method 
precision results are well within the desirable limit. It is concluded that the 
deliberately changed assay methods results are remains unaffected in small 
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variations which confirmed that all the methods are proficient to estimate sildenafil 
citrate Soft gelatin Capsules 50 mg. 
Stability Study 
  Standard and sample solutions to be used in the analytical method are 
scrutinized for their solution’s stability. This study was performed by injecting 
standard and sample solution for the period of 24 hours.  
Stability Studies was carried out at  0, 3, 6, 9, 12,15,18,21 hours and 24 hours 
time lapse of solutions preparation. The %RSD for sildenafil citrate standard  were 
found to be within the 0.059% and 0.120% and The %RSD for sildenafil citrate  
sample  were found to be within the 0.071% and 1.483% which were with the 
acceptance criteria of not more than 2%. The results of stability were shown in 
Table no: 7.9,7.10 and chromatogram were shown in Chromatogram No. 8.58 – 
8.75.  
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Table No 7.9: System suitability results and Cumulative % RSD results 
obtained for Stability of standard solution 
S. 
No. 
Time 
point 
Standard 
Solution 
area 
Results obtained 
Cumulative 
% RSD 
Tailing 
factor  
Theoretical 
plate  
01 0th hour 240467922 NA 0.95 6903 
02 3rd hour 240670302 0.059 0.95 6918 
03 6th hour 240602034 0.043 0.94 6940 
04 9th hour 240773026 0.053 0.98 6923 
05 12th hour 240744700 0.051 0.97 6929 
06 15th hour 240913809 0.064 0.96 6909 
07 18th hour 240411477 0.073 0.96 6889 
08 21st hour 239949634 0.124 0.94 6929 
09 24th hour 240330489 0.120 0.94 6938 
Limit NMT 2.0 % NMT 2.0 NLT 2000 
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Table No 7.10: System suitability results and Cumulative % RSD results 
obtained for Stability of sample solution 
S. 
No. 
Time 
point 
Sample 
Solution 
area 
Results obtained 
Cumulative 
% RSD 
Tailing 
factor  
Theoretical 
plate  
01 0th hour 256661227 NA 0.95 6906 
02 3rd hour 256401938 0.071 0.97 6947 
03 6th hour 256749674 0.070 0.97 6908 
04 9th hour 257485261 0.181 0.94 6951 
05 12th hour 260634009 0.680 0.96 6936 
06 15th hour 261251360 0.839 0.97 6923 
07 18th hour 262832813 1.020 0.97 6935 
08 21st hour 264082144 1.181 0.96 6933 
09 24th hour 267271980 1.483 0.95 6911 
Limit NMT 2.0 % NMT 2.0 NLT 2000 
 
  System suitability result passes and the results obtained for stability of 
standard solution and sample solution are found within the acceptance criteria for the 
minimum period of 24 hours study. 
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10. SUMMARY AND CONCLUSION 
 A RP-HPLC method is developed and validated as per ICH guidelines for 
sildenafil citrate soft gelatin  capsule dosage form.  
 This validation of statistical parameter is found that the analytical procedure 
for Sildenafil Citrate Soft gelatin Capsules 50 mg meets system suitability 
requirements and acceptance criteria for Specificity, Linearity, Precision, Accuracy, 
Robustness, Ruggedness parameters and Solution stability.  
Considering all the fact the following parameter were finally fixed for this method 
Equipment                : High performance liquid chromatography(agilent 1260) 
Mobile phase             : Ammonium acetate :Acetonitrile 
Column : waters reliant C18, 15 cm x 4.6 mm, 5 µm 
Flow Rate : 1.0 mL/minute 
Pump mode : Isocratic 
Detector wavelength : 240 nm 
Injection volume : 20 µL 
Column Temperature : 25.0˚C 
 The proposed method was found to be rapid, accurate, precise, specific, 
robust, rugged and economical. The mobile phase is simple to prepare and 
economical. The sample recoveries in all formulations were in good agreement 
with their respective label claims and they suggested non-interference of 
formulation excipients in the estimation. This method is also having an advantage 
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than reported method that the retention time of the drugs is below 5 mins and the 
drugs can be assayed with the short time. Thus the method is not time consuming 
and can be used in laboratories for the routine analysis of combination drugs.
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